Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of subcutaneous JKN24011 in moderate to severe COPD
CTR20242416Phase 2Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JKN24011 in chronic obstructive pulmonary disease (COPD), sponsored by Quxin Biopharmaceutical. Started Aug 2024; status: active.
02
Drugs
JKN24011
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20242416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242416.